News

Press release - Genzyme: Four-Year Data from Phase 2 Trial ...

9 February 2012

Four-Year Data from Phase 2 Trial of Genzyme Gaucher Disease Oral Compound Suggest Sustained or Continued Improvement Across All Endpoints

09/02/2012

Genzyme, a Sanofi company, announced today four-year follow-up data from patients enrolled in the …

read more »

Press release: Protalix Announces New Clinical Data on Taliglucerase Alfa

9 February 2012

Protalix Announces New Clinical Data on Taliglucerase Alfa to be Presented at the WORLD Lysosomal Disease Network Symposium 09/02/2012

Protalix BioTherapeutics, Inc. announced today that new clinical data on taliglucerase alfa will be presented at …

read more »

EGA is now officially eligible to be involved in the acitivities of the EMA

21 December 2011

The EGA is pleased to announce that it received today from the EMA (European Medicines Agency) the confirmation that it complies with the criteria to be involved in the Agency’s activities.  For more information...

1st Regional Patient Meeting in Slovenia

21 November 2011

Dear Friends

I would like to thank you all who attended the first regional meeting of Gaucher patients, on 5th November 2011, in Čatež, Slovenia. I would also like to thank the colleagues from Genzyme for logistical and financial support.

More …

read more »

New EGA Website launched

1 November 2011

The European Gaucher Alliance (EGA) is delighted to announce the launch of our new website resource. The new site contains a wealth of information on the work of the EGA and holds informative profiles of each member country association.

This launch …

read more »

Cerezyme Emergency Treatment Program (CETP)

4 January 2011

The CETP was set up last year for the benefit of Gaucher disease patients at high-risk for the development of progressive disease or complications and without access to alternative treatments during the period of Cerezyme shortage

CETP will be …

read more »